Cupid Ltd. Hits Record High Following Upward

Cupid Limited, a leading manufacturer of contraceptives and healthcare diagnostics, has seen its shares touch a fresh 52-week high after revising its financial projections upward for FY27. The company raised its annual revenue target to ₹800 crore and net profit guidance to ₹250 crore, spurred by strong performance in both domestic and international markets. The announcement comes on the heels of impressive Q1 FY27 results—where net profit grew nearly threefold year-on-year—as well as the stock's recent inclusion in key benchmark indices, which attracted significant institutional investor interest. To sustain this growth trajectory, Cupid Limited is actively expanding its manufacturing footprint, including a new 170,000 sq. ft. facility designed to scale up production of nitrile gloves and medical diagnostic kits. Having secured major international regulatory approvals, including European IVDR CE certifications, the company is broadening its retail reach across global and domestic distribution networks. With these strategic expansions underway, the management remains firmly positioned to meet its ambitious target of achieving ₹1,500 crore in total revenue by FY29.